Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma

Table 1 Characteristics of patients (n = 104)

Characteristics	Data, n (%)
Age (yr)	59 ± 9 (mean ± SD)
Sex
Male	72 (69.2)
Female	32 (30.8)
Location of tumors
Head	86 (82.7)
Body	8 (7.7)
Body and tail	10 (9.6)
Type of operation
Pancreaticoduodenectomy	48 (46.2)
Distal pancreatectomy	10 (9.6)
Exploratory laparotomy and biopsy	46 (44.2)

Table 2 CA19-9 levels in patients with resectable and unresectable pancreatic cancer

Group	n	CA19-9 (U/mL)			Wilcoxon
		Q1	Q2	Q3	Z	P
Resectable	58	15.57	130.10	270.25	-5.132	0.000
Unresectable	46	361.30	656.20	1780.00

Table 3 Positive and negative predictive values of CA19-9 at the cut-off point

		Resection		Total	Predictive value
		Yes	No
CA19-9 (U/mL)	≤ 353.15	54	10	64	84.38% (+)
	> 353.15	4	36	40	90.00% (-)
Total		58	46	104